Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Rebecca, Chien"'
Publikováno v:
Genetic Testing and Molecular Biomarkers. 16:605-614
Since the late 1990 s, there has been an unprecedented growth in the development of new molecular and proteomic assays for clinical decision making. Despite the thousands of tests available, a standardized, well-defined, and coherent evaluation frame
Autor:
John, Hornberger, William J, Gradishar, Michael D, Alvarado, Rebecca, Chien, Tiffany M, Yu, Hialy R, Gutierrez
Publikováno v:
Journal of the National Cancer Institute. 105(2)
Autor:
Mark Friedmann, Rebecca Chien, Sacha Satram-Hoang, Leona C. Han, Carolina M. Reyes, Ashwini Shewade, John Hornberger
Publikováno v:
Leukemialymphoma. 53(12)
A recent phase III trial demonstrated that maintenance rituximab® therapy after response to first-line treatment with rituximab plus chemotherapy (R-chemo) increases progression-free survival (PFS) for follicular non-Hodgkin lymphoma (f-NHL). A cost
National guidelines recommend a 21-gene recurrence score (RS) to aid in adjuvant treatment decision in patients with estrogen receptor (ER) -positive, lymph node (LN) -negative early-stage breast cancer (ESBC). This study was performed to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ab8c36c4df4968292c79ac9e0a319d6
https://europepmc.org/articles/PMC3092466/
https://europepmc.org/articles/PMC3092466/
Publikováno v:
The Breast Journal. 19:220-221
Autor:
John Hornberger, Leona C. Han, M. Friedmann, Rebecca Chien, Carolina M. Reyes, R. J. Hornberger, Sacha Satram-Hoang
Publikováno v:
Journal of Clinical Oncology. 29:e18544-e18544
e18544 Background: Maintenance rituximab (R) therapy every two months for 2 years after chemoimmunotherapy (R-Chemo) has demonstrated improved progression-free survival (PFS) in previously untreate...
Publikováno v:
Journal of Clinical Oncology. 29:491-491
491 Background: Uncertainty exists regarding the use of adjuvant therapy in patients with stage II colon cancer. To assist decision making, we compared quality-adjusted life expectancy and costs associated with using a multigene recurrence score (RS)
PCN13 COST-BENEFIT ANALYSIS OF A 21-GENE RECURRENCE SCORE FOR EARLY STAGE BREAST CANCER IN SINGAPORE
Publikováno v:
Value in Health. 13:A512
Publikováno v:
Journal of Clinical Oncology. 28:e382-e382
TO THE EDITOR: Lo et al reported the first prospective treatment impact study of the 21-gene recurrence score (RS) assay (Oncotype DX, Genomic Health, Redwood City, CA) in the United States, administered to 89 women. They cited our economic analyses